Weimin Tang, PhD

PRINCETON, Maryland, United States
Dr. Weimin Tang is CBO of I-Mab Biopharma, a clinical stage biotech company focusing on Immunology and Oncology. He served as Interim CEO/Head of US Business Development at Jiangsu Hengrui Medicine previously, and built the Hengrui US business development team and clinical operation in Princeton, NJ. He was trained as a cancer biologist with a PhD in Biochemistry from CS Yang’s lab at Rutgers University. He has accumulated more than 25 years of research and business management experience with global pharmaceutical companies and biotechs such as Synaptic Pharmaceutical, BMS, Johnson & Johnson, Sanofi, American Cyanamid, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his career, he expanded his function from basic biology to high throughput screening, DMPK, Clinical Development and business management. During his 10+ years of Business Development, he has closed deals totaling over $10B, ranging from discovery to Ph3 programs. Dr. Tang received his Bachelor's Degree from Zhejiang University, and his Master Degree from Chinese Academy of Sciences.
Speaking In
10:45 AM - 12:00 PM (PDT)
Monday, June 13
Partnering activity in China continued to accelerate in 2021 with 658 deals generating a record $42…
Upper Level, Session Room 6B